Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2021

View Archived Issues

TRIM47 targeting shows potential for treating breast cancer refractory to endocrine therapy

Gilead describes new antiviral nucleoside analogues

New GCN2 inhibitors identified at Black Belt TX

As targeted options expand, making the best match, and the most matches

Targeting GCN2 or elevating tRNAGly levels may be useful in Charcot-Marie-Tooth disease

IP6K regulates circulating phosphate and intracellular ATP in mammals

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents antibodies binding IL-4RA

Single-cell transcriptome of human melanocytes during development, aging and malignancy

Discovery of novel compounds with potent activity against resistant bacteria

TSHA-104 AAV9 gene-replacement therapy for Leigh syndrome shows promising results

MEGs and MBK-2 clusters regulate P granule dynamics and coarsening

Rasarfin, a dual Ras and ARF6 inhibitor with promising antitumor activity

NIDA agrees to screen Initiator Pharma's preclinical assets for anti-addictive properties

Researchers report improved DHODH inhibitors, anti-coronavirus activity

Kissei Pharmaceutical discovers EGLN1 inhibitors

SpectrumX reports in vitro neutralizing efficacy of SPC-069 against SARS-CoV-2 variants

ETX-0462 is a potent antibiotic against Pseudomonas aeruginosa

BET protein inhibition can reverse CAR T-cell exhaustion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...